-
JC-1 Mitochondrial Membrane Potential Assay Kit
2026-09-21
This scenario-based guide explains how SKU K2002 supports mitochondrial membrane potential measurement when viability results are inconsistent or mechanistic interpretation is unclear. It covers JC-1 principles, controls, workflow optimization, data interpretation, and practical criteria for selecting a reliable mitochondrial membrane potential assay.
-
Genotyping for Mechanistic Infection Research
2026-09-21
Mechanistic infection studies increasingly depend on linking host pathways to genotype-defined phenotypes. This thought-leadership article examines how findings on cystathionine-β-synthase and hydrogen sulfide in Staphylococcus aureus-induced udder infection can inform mouse-model strategy, while showing how the Direct Mouse Genotyping Kit supports rapid, scalable genotype assignment before functional validation.
-
Mouse Tissue Lysis Kit (K1038) Workflow
2026-09-20
The Mouse Tissue Lysis Kit (K1038) prepares lysates from mouse tail, toe, or ear tissue for direct PCR-based genotyping without a separate DNA extraction or purification step. It is intended for molecular biology research and DNA analysis, not diagnostic, clinical, or medical use.
-
JC-1 and Mitochondrial Signals in Bladder Cancer
2026-09-19
A translational perspective on how mitochondrial membrane potential measurement can strengthen mechanistic studies of LRG1-driven neutrophil dysfunction, pathological angiogenesis, and therapy resistance in bladder cancer.
-
SM-102: A Mechanism-to-Assay Guide for mRNA Delivery
2026-09-18
SM-102 is examined through a mechanism-to-assay framework for mRNA delivery, with practical guidance on formulation controls, endosomal escape interpretation, and comparison with polyphenol-based nucleic acid nanoparticles.
-
Preserving Protein Mechanism in Tumor Microenvironments
2026-09-18
A translational framework for studying CAF-driven chemoresistance through native protein extraction, interaction assays, and metabolic validation, with practical guidance on selecting Cell lysis buffer for WB and IP.
-
Heparin Sodium for Nanovesicle Uptake Assays
2026-09-17
Heparin sodium serves both as a calibrated anticoagulant for coagulation experiments and as a mechanistic competition probe for heparan sulfate proteoglycan-dependent nanovesicle uptake. This workflow connects anti-factor Xa and aPTT readouts with practical cell-uptake assays while separating evidence-backed findings from optimization recommendations.
-
Clodronate Liposomes in Macrophage Research
2026-09-17
Use Clodronate Liposomes to test whether macrophages are necessary for age-related defects in phagocytosis, tissue inflammation, or repair. This practical guide combines route-aware in vivo macrophage depletion with controls, depletion checks, and assay choices informed by a recent aging study.
-
Caspase-4 Colorimetric Assay Kit Workflow
2026-09-16
Turn LEVD-dependent caspase-4 activity into a practical 400–405 nm readout for pyroptosis, inflammation, and mechanism-focused cell-death studies. This workflow also shows how to use the assay alongside ER-targeted enzyme-instructed self-assembly research without conflating ER stress with caspase-4 activation.
-
Streptozotocin (STZ) in Diabetes Research
2026-09-16
Streptozotocin, or STZ, is a DNA-alkylating nitrosourea used to induce pancreatic β-cell injury and experimental diabetes mellitus. Its controlled use can connect β-cell cytotoxicity with downstream studies of hyperglycemia, neuropathy, and neuroinflammation, but STZ is not itself a TBK1 inhibitor or a complete replica of human diabetes.
-
MTSEA-biotin and the Next Layer of RNA Biology
2026-09-15
Site-specific RNA polymerase II CTD phosphorylation is a regulatory system, not a single transcriptional switch. This thought-leadership perspective explains how MTSEA-biotin can complement FeaSion-style discovery by testing accessibility and conformational hypotheses around candidate CTD regulators, while defining the controls and limitations required for translational confidence.
-
Integrating Transcriptomics and Cardiotoxicity Phenotypes
2026-09-15
Tsai and colleagues developed an integrated screening framework that combines functional, cytotoxicity, transcriptomic, and exposure-oriented analyses in human iPSC-derived cardiomyocytes. Across 464 chemicals, the study shows that transcriptomic points of departure can complement cardiac phenotypes for hazard prioritization and mechanistic interpretation without replacing conventional risk assessment.
-
Doxorubicin Workflows for Cancer and Senescence Models
2026-09-14
Doxorubicin, also known as Adriamycin, is a mechanistically defined benchmark for DNA damage, apoptosis, and drug-response studies. This guide shows how to use it in cancer assays and as a carefully controlled stress-model component when evaluating senolytic or senomorphic nanovesicles.
-
Cell Lysis Strategy for CAF Chemoresistance
2026-09-14
Mechanistic studies of cancer-associated fibroblasts increasingly depend on preserving both protein abundance and protein–protein interactions. This article connects the ANGPTL4–IQGAP1 chemoresistance axis in prostate cancer with practical, translationally oriented protein extraction strategy using Cell lysis buffer for WB and IP.
-
Ceftolozane/Tazobactam: Evidence and Research Insights
2026-09-13
This review examines how ceftolozane/tazobactam combines a PBP-focused cephalosporin with β-lactamase inhibition to address important resistant Gram-negative pathogens. Its value lies in integrating chemistry, microbiology, pharmacokinetics, pharmacodynamics, clinical trials, and safety evidence while defining where activity should not be overgeneralized.